Hemophilia B

Agreement Signed to Develop Factor IX Gene Therapy

Published in Blood Weekly, March 30th, 2000

BTG International Inc., Gulph Mills, Pennsylvania, announced that it has signed a license agreement with Avigen, Inc., covering the use of the gene for Factor IX, an important blood protein, in Avigen's proprietary gene therapy delivery system, which it is developing for the treatment of Hemophilia B.

The Factor IX gene sequence was discovered by researchers at the University of Oxford in the United Kingdom, and the University of Washington in Seattle, and was acquired by BTG for commercialization.

Hemophilia B is caused by a deficiency or defect in the Factor IX gene, one of a number of proteins involved in blood clotting. It is an inherited...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2000-03-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry